Cardiovascular consequences of drugs used for the treatment of diabetes: potential promise of incretin—based therapies
- 31 August 2009
- journal article
- review article
- Published by Elsevier BV in Journal of the American Society of Hypertension
- Vol. 3 (4), 245-259
- https://doi.org/10.1016/j.jash.2009.04.001
Abstract
No abstract availableKeywords
This publication has 144 references indexed in Scilit:
- 10-Year Follow-up of Intensive Glucose Control in Type 2 DiabetesNew England Journal of Medicine, 2008
- Is the Combination of Sulfonylureas and Metformin Associated With an Increased Risk of Cardiovascular Disease or All-Cause Mortality?Diabetes Care, 2008
- Intensive Blood Glucose Control and Vascular Outcomes in Patients with Type 2 DiabetesNew England Journal of Medicine, 2008
- Cardiovascular disease risk in type 2 diabetes mellitus: insights from mechanistic studiesThe Lancet, 2008
- New Drugs for the Treatment of Diabetes MellitusCirculation, 2008
- Sitagliptin, a DPP-4 inhibitor for the treatment of patients with type 2 diabetes: a review of recent clinical trialsCurrent Medical Research and Opinion, 2008
- Efficacy and Safety of Incretin Therapy in Type 2 DiabetesJAMA, 2007
- Effect of Chronic Central Administration of Glucagon‐Like Peptide‐1 (7–36) Amide on Food Consumption and Body Weight in Normal and Obese RatsObesity Research, 1998
- Truncated GLP-1 (proglucagon 78?107-amide) inhibits gastric and pancreatic functions in manDigestive Diseases and Sciences, 1993
- The effect of hypoglycemia on myocardial ischemic injury during acute experimental coronary artery occlusion.Circulation, 1975